Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study of Lutonix 035 Drug Coated Balloon (DCB) and In.Pact DCBs in patients with symptomatic peripheral artery disease undergoing femoropopliteal intervention.

Next Previous
Trial Profile

A retrospective study of Lutonix 035 Drug Coated Balloon (DCB) and In.Pact DCBs in patients with symptomatic peripheral artery disease undergoing femoropopliteal intervention.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Feb 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Peripheral arterial disorders
  • Focus Therapeutic Use

Most Recent Events

  • 12 Feb 2016 New trial record
  • 09 Feb 2016 According to a Bard Peripheral Vascular Inc. media release results of retrospective study of Lutonix 035 Drug Coated Balloon (DCB) and In.Pact DCBs in patients with symptomatic peripheral artery disease undergoing were presented at Leipzig International Course (LINC).
  • 09 Feb 2016 Results published in the Bard Peripheral Vascular Inc. media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top